SKB BIO-B (06990): SKB445 New Drug Clinical Trial Application Approved by the National Medical Products Administration.
Colombotech Biotech-B (06990) announcement, the company's board of directors is pleased to announce that the company has...
SKB BIO-B (06990) announced that the Board of Directors of the company is pleased to announce that on January 20, 2025, the company received a clinical trial notification letter from the National Medical Products Administration Drug Evaluation Center approving the company's application for clinical trials of the innovative drug SKB445.
SKB445 is a novel ADC drug developed by the company using the OptiDC platform technology targeting specific biological markers. It has shown promising efficacy and safety in preclinical studies and is intended for the treatment of advanced solid tumors.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
